secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001798749-23-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics appoints Donald Santel to Board of Directors
------------------------------------------------------------------

- Santel appointed as Class I director effective Jan 19, 2023; term expires at 2025 annual meeting.
- He joins the Nominating and Corporate Governance Committee; other committees unchanged.
- Santel brings over 40 years biopharma experience, including CoTherix and Hyperion (PAH focus) and Oyster Point Pharma.
- He will receive standard non-employee director equity and cash compensation for 2023.
- Board determined Santel is independent under Nasdaq listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000005/0001798749-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000005/tmb-20230119x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer